| Similar Articles |
|---|
 |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.   |
BusinessWeek
May 26, 2011
Brendan Greeley |
Tyler Cowen, America's Hottest Economist The George Mason University professor has written a bestseller, The Great Stagnation, keeps an influential blog, and reads way too many books |
The Motley Fool
December 31, 2004
Selena Maranjian |
The Future of Newspapers Blogs and the Web may hurt or change newspapers. These developments are not only interesting -- they also matter to some investors. |
The Motley Fool
December 4, 2007
Brian Orelli |
An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications. |
The Motley Fool
September 9, 2010
Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
The Motley Fool
June 28, 2004 |
Teaching Kids How to Invest Your kids have time on their side, so give them a head start in investing. |
Search Engine Watch
June 29, 2009
Ron Jones |
Blogs and Blogging 101, Part 1 Search engines will reward a site that has quality content with good rankings. For many sites, one of the easiest ways to add that quality content on a consistent basis is by starting a blog. |
Financial Planning
October 1, 2005
Pat Olsen |
The Financial Blogger Web logs can serve as a cutting-edge marketing tool and communications vehicle for financial advisers. But there are caveats to consider as well. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Reason
April 2008
Ronald Bailey |
Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians. |
Chemistry World
June 6, 2013
Phillip Broadwith |
Big data to sniff out drug marketing fraud The US Food and Drug Administration is offering a contract for a company to collect and analyze data on pharma companies' promotional activities. The aim is to use this big data approach to spot off-label marketing and other forms of marketing fraud. |
PC Magazine
February 8, 2007
Russell Morgan |
Business Blogging Here's how your small business can benefit from blogs. |
PC Magazine
August 16, 2006
Captain Jack Sparrow |
Blog Nation In only a few short years, blogging has become a vital part of many Americans' lives, according to a phone survey of 7,012 people by the Pew Internet & American Life Project. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
December 22, 2006
Stephen Albainy-Jenei |
Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use. |
Chemistry World
May 14, 2015
Rebecca Trager |
FDA accused of violating drug company's freedom of speech The US Food and Drug Administration is under pressure to reconsider its policy prohibiting pharmaceutical companies from promoting 'off-label' uses of their products. |
Chemistry World
May 27, 2015
Phillip Broadwith |
Label laundry It's been an interesting month in the world of off-label pharmaceuticals. |
The Motley Fool
January 3, 2005
Alyce Lomax |
Blogs Booming? Although investors who have taken stock in newspapers and other media companies ought to keep a careful eye on the trend, for the time being, blogging itself is still an area where nobody's making much money. |
The Motley Fool
November 22, 2006
Brian Lawler |
How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
BusinessWeek
October 18, 2004
John Carey |
"Off-Label" -- And Out Of Bounds? When drugmakers promote products for unproven uses, they may be courting trouble. How restrictive should the regulations be? |
The Motley Fool
October 9, 2008
Brian Orelli |
When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management. |
The Motley Fool
April 12, 2004
Seth Jayson |
Gannett's Ad-vantageous Q1 First-quarter earnings for Gannett, publisher of USA Today and hundreds of other newspapers, show strong increases in advertising revenues across every segment of the company. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
HBS Working Knowledge
November 28, 2005
Katherine Heires |
Does Your Company Belong in the Blogosphere? Here is advice from executive experts on helping your company realize the full benefits of blogging. |
Entrepreneur
February 2008
Guy Kawasaki |
Get Your Company Blog On Your company's blog could be one of your strongest marketing tools - so get talking. |
Search Engine Watch
March 9, 2005
Chris Sherman |
A Cool Blog Discovery Tool There's a lot of great content out there on those millions of blogs, so finding the good ones related to your own interests can be a challenge to many blog search engines. But this set of tools takes a different approach to blog searches. |
BusinessWeek
December 11, 2006
Michael Arndt |
Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West. |
BusinessWeek
November 29, 2004
Carey & Barrett |
Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do. |
InternetNews
January 2, 2007
David Needle |
Google May Open Up Blog It was a big year for Google's own blog (even if you don't think it really is one). |
The Motley Fool
January 21, 2004
Alyce Lomax |
Knight Ridder's Slow News Day Are tough ad times almost over for the newspaper company? |
Fast Company
May 2005
Danielle Sacks |
Blogging Up Self-proclaimed "blogologist" Alex Halavais on how to career-blog without it coming back to haunt you. |
Managed Care
July 2007
Alan Adler |
Why Blogs? Don't dismiss this development in Web communication. Blogs -- the best of them -- conduct serious and extensive discussions of health care policy and provide important new information. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Entrepreneur
May 2008
John Jantsch |
The New Frontier These days, everyone's blogging. Is it time for your business to join the club? |
The Motley Fool
October 19, 2010
Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
The Motley Fool
January 8, 2008
Brian Orelli |
A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain. |
BusinessWeek
April 25, 2005
Barrett & Carey |
"Off-Label" Drugs: J&J Is Pushing The Envelope Recommending uses for its drugs not intended when approved by the FDA. |
CIO
June 1, 2006
Michael Fitzgerald |
Welcome to My Blog Blogging isn't the same as writing a memo or a message in the corporate newsletter. And while it may not be as revolutionary as some make it out to be, there's still value there. Here's how to get started and how to do it right. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
April 20, 2004
Selena Maranjian |
Wal-Mart Bigger Than Itself Not many companies are the subjects of academic conferences. |
The Motley Fool
March 24, 2004
Selena Maranjian |
How to Open a Brokerage Account When you're ready to invest, you can do so easily. Tips on how to open a brokerage account. |
The Motley Fool
July 13, 2004
Selena Maranjian |
Wanted: Wall Street Analysts Are Wall Street analysts, the "sell-side" analysts who work for brokerages, an endangered species? Should you care? For investors expect to see less research available on many smaller companies. |
IndustryWeek
August 1, 2006
Traci Purdum |
Sun Microsystems' CEO Blogs Jonathan Schwartz, president and CEO of Sun Microsystems Inc., reaches employees, partners and customers via his twice-weekly blog. |
The Motley Fool
February 22, 2011
Brian Orelli |
A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S. |
InternetNews
September 9, 2005
Steven Warren |
The Benefits of Corporate Blogging Allowing employees to blog can generate advantages for your company. Here's some rules to follow. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
AskMen.com
Jim Bauer |
How To: Start A Blog Transaction costs are next to nothing in the digital age, and with just a few key strokes and mouse clicks, you could be on your way to becoming a famous blogger. |
The Motley Fool
January 27, 2004
Seth Jayson |
NY Times' Slim Pickings Media conglomerate weathers storms to post modest gains |
The Motley Fool
March 30, 2009
Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. |
